Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT00553969

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease (DETECT)

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)

Sponsor: GlaxoSmithKline

Conditions Pre-hypertension

Interventions carvedilol phosphate carvedilol phosphate and lisinopril lisinopril placebo and placebo

Updated 9 times since 2017 Last updated: Mar 23, 2018 Started: Nov 30, 2007 Primary completion: Sep 30, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Pre-hypertension, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 4 earlier versions

Nov 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Nov 2019 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University of Minnesota

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States